<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.3"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Bioelectron Med</journal-id><journal-id journal-id-type="iso-abbrev">Bioelectron Med</journal-id><journal-title-group><journal-title>Bioelectronic Medicine</journal-title></journal-title-group><issn pub-type="epub">2332-8886</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40405320</article-id><article-id pub-id-type="pmc">PMC12100802</article-id>
<article-id pub-id-type="publisher-id">175</article-id><article-id pub-id-type="doi">10.1186/s42234-025-00175-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>Continuous theta burst stimulation in the treatment of epilepsia partialis continua: a case series</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Algoet</surname><given-names>Chlo&#x000e9;</given-names></name><address><email>chloe.algoet@ugent.be</email><email>ch.algoet@hotmail.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Carrette</surname><given-names>Sofie</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Meurs</surname><given-names>Alfred</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mertens</surname><given-names>Ann</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Hemelsoet</surname><given-names>Dimitri</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Boon</surname><given-names>Paul</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Vonck</surname><given-names>Kristl</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/00cv9y106</institution-id><institution-id institution-id-type="GRID">grid.5342.0</institution-id><institution-id institution-id-type="ISNI">0000 0001 2069 7798</institution-id><institution>Department of Neurology, </institution><institution>Ghent University, </institution></institution-wrap>Corneel Heymanslaan 10, Ghent, 9000 Belgium </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/02c2kyt77</institution-id><institution-id institution-id-type="GRID">grid.6852.9</institution-id><institution-id institution-id-type="ISNI">0000 0004 0398 8763</institution-id><institution>Department of Electrical Engineering, </institution><institution>Eindhoven University of Technology, </institution></institution-wrap>Eindhoven, the Netherlands </aff></contrib-group><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="pmc-release"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>11</volume><elocation-id>12</elocation-id><history><date date-type="received"><day>7</day><month>3</month><year>2025</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p id="Par1">Epilepsia partialis continua (EPC) is a medication-resistant form of focal status epilepticus (SE), causing significant morbidity. This case series explored whether continuous theta burst stimulation (cTBS) could reduce seizure activity in patients with EPC.</p></sec><sec><title>Methods</title><p id="Par2">Three patients with motor EPC (2M/1F) underwent an accelerated cTBS protocol over four consecutive days (five 40-s trains/day, 5Hz bursts, 3 pulses at 50Hz/burst). Stimulation targeted the epileptogenic zone using a figure-of-eight coil at 80% of the resting motor threshold. Electroencephalography (EEG) was conducted before and after each session. Seizure frequency, intensity, adverse events (AEs), seizure diaries, and follow-up data were assessed.</p></sec><sec><title>Results</title><p id="Par3">cTBS did not interrupt EPC in any patient. One patient reported a 17% reduction in seizure frequency. Another noted mild improvement in shoulder jerks, and a third reported reduced arm tension, though without clinical confirmation. EEG showed no significant changes. One patient experienced seizures during stimulation, and another reported worsening of pre-existing headaches.</p></sec><sec><title>Conclusion</title><p id="Par4">In this small case series, a four-day accelerated cTBS protocol did not yield clinically meaningful seizure control in EPC. Further research is needed to evaluate TMS and TBS in SE and EPC, where a significant treatment gap remains.</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Continuous theta burst stimulation</kwd><kwd>Repetitive transcranial magnetic stimulation</kwd><kwd>Epilepsia partialis continua</kwd><kwd>EPC</kwd><kwd>Status epilepticus</kwd><kwd>Neuromodulation</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100003130</institution-id><institution>Fonds Wetenschappelijk Onderzoek</institution></institution-wrap></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution>4BRAIN</institution></funding-source></award-group></funding-group><funding-group><award-group><funding-source><institution-wrap><institution-id institution-id-type="FundRef">https://doi.org/10.13039/501100007229</institution-id><institution>Bijzonder Onderzoeksfonds UGent</institution></institution-wrap></funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Feinstein Institute for Medical Research 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par29">Status epilepticus (SE) is defined as an abnormally prolonged seizure episode, arising from dysfunction of mechanisms responsible for seizure termination, spread or recurrence of seizures (Trinka et al. <xref ref-type="bibr" rid="CR31">2015</xref>; Lowenstein et al. <xref ref-type="bibr" rid="CR19">1998</xref>; Hanhan et al. <xref ref-type="bibr" rid="CR11">2001</xref>). Epilepsia partialis continua (EPC) is a specific subclass of focal motor status, marked by continuous epileptic fragments (motor or sensory), while consciousness remains intact (Trinka et al. <xref ref-type="bibr" rid="CR31">2015</xref>; Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>). These episodes persist for &#x02265;&#x02009;1 h and are associated with localized epileptic activity, typically causing seizures in a specific body part (Trinka et al. <xref ref-type="bibr" rid="CR31">2015</xref>; Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>). One notable aspect of EPC is its heightened sensitivity to external stimuli, including sensory input and movement (Mameni&#x00161;kien&#x00117; and Wolf&#x000a0;<xref ref-type="bibr" rid="CR20">2017</xref>). Symptoms persist during sleep and are often accompanied by postictal weakness (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>; Khan et al. <xref ref-type="bibr" rid="CR14">2024</xref>). According to a recent European survey, the time course of EPC can be categorized into four distinct types: solitary episode, chronic repetitive non-progressive, chronic persistent non-progressive and chronic progressive (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>).</p><p id="Par30">Although formal epidemiological data are lacking, literature suggests EPC is rare, accounting for &#x0003c;&#x02009;3% of all epilepsy cases (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>). In adults, the incidence appears to be slightly higher in males compared to females; however, no significant gender differences have been observed in children (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi April <xref ref-type="bibr" rid="CR25">2024</xref>; Khan et al. <xref ref-type="bibr" rid="CR14">2024</xref>;&#x000a0;Kravljanac et al. <xref ref-type="bibr" rid="CR5">2013</xref>). In pediatric cases, inflammatory and immune-mediated disorders are the primary etiologies, whereas in adults, structural abnormalities are the most common cause of EPC (30&#x02013;60% of cases)(Muthaffar and Alyazidi April <xref ref-type="bibr" rid="CR25">2024</xref>; Kravljanac et al. <xref ref-type="bibr" rid="CR5">2013</xref>). Other potential causes include metabolic, genetic or unknown factors (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>).</p><p id="Par31">The prognosis of EPC largely depends on the underlying cause, with better outcomes in reversible etiologies (Khan et al. <xref ref-type="bibr" rid="CR14">2024</xref>). In pediatric patients, prognosis appears to be worse than in adults, with approximately 64.7% experiencing neurological consequences and 15.7% resulting in fatal outcomes (Khan et al. <xref ref-type="bibr" rid="CR14">2024</xref>; Kravljanac et al. <xref ref-type="bibr" rid="CR5">2013</xref>). In this population, predictors for neurological consequences include interictal EEG abnormalities and periodic EEG patterns (Kravljanac et al. <xref ref-type="bibr" rid="CR5">2013</xref>). For lethal outcomes in children, predictors are the onset of EPC during the terminal phase of disease and the need for intensive therapy (Kravljanac et al. <xref ref-type="bibr" rid="CR5">2013</xref>).</p><p id="Par32">The treatment of EPC is primarily guided by its underlying etiology, as the condition often proves resistant to pharmacotherapy (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>). While benzodiazepines can effectively interrupt EPC, they are unsuitable for long-term therapy (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>). A European survey indicated that topiramate and levetiracetam are among the most effective options for continuous treatment in this patient population (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>). In cases of Rasmussen encephalitis, surgical isolation of the affected hemisphere remains the only curative option, with a success rate of up to 80% in younger patients (Mameni&#x00161;kien&#x00117; and Wolf <xref ref-type="bibr" rid="CR20">2017</xref>; Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>). Immunomodulatory therapy may be considered if antiseizure medications (ASMs) fail or if the clinical presentation suggests an underlying autoimmune condition (Muthaffar and Alyazidi <xref ref-type="bibr" rid="CR25">2024</xref>).</p><p id="Par33">Given the resistance to pharmacotherapy, there is growing interest in alternative treatments for EPC. Transcranial magnetic stimulation (TMS) is a non-invasive neurostimulation technique that generates a strong magnetic field (&#x000b1; 2 Tesla) by passing a current through a coil of copper wire (Mattioli et al. <xref ref-type="bibr" rid="CR22">2024</xref>; Tsuboyama et al. <xref ref-type="bibr" rid="CR32">2020</xref>). Based on Faraday&#x02019;s law of electromagnetic induction, application to the scalp induces a weak secondary current (50&#x02013;150 V/m) in the brain, modulating neuronal excitability (Mattioli et al. <xref ref-type="bibr" rid="CR22">2024</xref>; Tsuboyama et al. <xref ref-type="bibr" rid="CR32">2020</xref>). TMS can be delivered in a repetitive format (rTMS), utilizing either low frequency (LF-rTMS, &#x02264;&#x02009;1 Hz) or high frequency (HF-rTMS, &#x02265;&#x02009;5 Hz) stimulation.</p><p id="Par34">Theta burst stimulation (TBS) is a more recently introduced rTMS protocol, that involves delivering three bursts of pulses at a high frequency (50 Hz), with an interburst interval of 20 ms (5 Hz) (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>; Cole et al. <xref ref-type="bibr" rid="CR4">2024</xref>). TBS offers significant advantages over standard rTMS, including shorter stimulation times (1&#x02013;10 min. compared to 20&#x02013;45 min.), lower stimulation intensity, and longer-lasting cortical effects (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>; Liu et al. <xref ref-type="bibr" rid="CR18">2024</xref>). Moreover, TBS appears to demonstrate similar efficacy and safety compared to standard rTMS in treating depression in both children and adults (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>; Liu et al. <xref ref-type="bibr" rid="CR18">2024</xref>).</p><p id="Par35">Continuous TBS (cTBS) involves delivering either 300 pulses over 20 s or 600 pulses over 40 s without interruption (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>; Huang et al. <xref ref-type="bibr" rid="CR12">2005</xref>). This protocol is believed to induce long-term depression (LTD), reducing cortical excitability for ~&#x02009;20 min. (300 pulses) or up to 1&#x02009;h (600 pulses). Intermittent TBS (iTBS), on the other hand, delivers 30 pulses over 2&#x02009;s, repeated every 10 s, with a total of 600 pulses (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>). This protocol is associated with long-term potentiation (LTP) and enhances motor cortex excitability for at least 15 min. (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>; Park JH <xref ref-type="bibr" rid="CR28">2022</xref>).</p><p id="Par36">Overall, TBS is considered a safe neuromodulation technique. The estimated crude risk of mild adverse events (AEs) is approximately 1.1%, which is comparable to the risk associated with HF-rTMS protocols (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>). Common side effects include headaches and dizziness (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>). Although TBS theoretically carries a higher potential for seizure induction than rTMS, it can also be viewed as safer because it uses fewer pulses, has a shorter duration and operates at lower intensity levels (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>). This is supported by literature reporting a low crude risk of seizure per session, estimated at just 0.02% (Chung et al. <xref ref-type="bibr" rid="CR3">2015</xref>).</p><p id="Par37">In 2018, the U.S. Food and Drug Administration (FDA) approved iTBS targeting the dorsolateral prefrontal cortex as a treatment for therapy-resistant depression (Cole et al. <xref ref-type="bibr" rid="CR4">2024</xref>). However, no cTBS protocols have been approved to date (Cole et al. <xref ref-type="bibr" rid="CR4">2024</xref>). To the best of our knowledge, three sham-controlled trials have evaluated cTBS targeting either the epileptogenic focus or the cerebellum as a treatment for drug-resistant epilepsy (DRE) (Carrette et al. <xref ref-type="bibr" rid="CR2">2022</xref>; Gundogdu Celebi et al. <xref ref-type="bibr" rid="CR8">2023</xref>; Wang et al. <xref ref-type="bibr" rid="CR33">2025</xref>). While the initial findings are promising, further research is needed to assess efficacy and mechanisms. We recently performed a systematic review and found 17 patients with EPC who were treated with rTMS, with a cessation rate of 12/17 (70.6%) (Algoet et al. <xref ref-type="bibr" rid="CR1">2025</xref>). However, there are currently no published case reports specifically investigating the use of TBS in EPC patients. In this report, we present three patients with EPC treated with cTBS in order to observe its potential effectiveness and safety profile.</p></sec><sec id="Sec2"><title>Material and methods</title><sec id="Sec3"><title>Participants</title><p id="Par38">Three patients with EPC were recruited from Ghent University Hospital. The study was approved by the local ethics committee, and all participants provided written informed consent.</p></sec><sec id="Sec4"><title>Stimulation protocol</title><p id="Par39">Accelerated cTBS was delivered using a figure-of-eight coil (MagVenture, Farum, Denmark), positioned over the epileptogenic focus at the motor cortex. The stimulation target was initially identified through prior presurgical evaluation incorporating clinical, radiological, and EEG data. However, for this study, targeting was further refined according to clinical presentation: when motor jerks were localized to the hand, the corresponding hand motor area was identified by eliciting motor responses with the TMS coil at the same location. Neuronavigation or source localization techniques were not used.</p><p id="Par40">Stimulation intensity was set at 80% of resting motor threshold (rMT), which was determined individually prior to treatment. Each treatment session consisted of five trains of 600 pulses, administered over 40 s with an interstimulus interval (ISI) of 600 s. Pulses were delivered in 5 Hz bursts, each composed of three pulses at 50 Hz. This stimulation protocol was adapted from psychiatric therapeutic protocols. We hypothesized that applying these parameters in a cTBS rather than iTBS format could yield therapeutic benefits for seizure control in EPC. The protocol was applied once daily for four consecutive days.</p><p id="Par41">Patients were instructed to maintain adequate sleep and avoid caffeine before sessions.</p></sec><sec id="Sec5"><title>Outcome measures</title><p id="Par42">Electroencephalogram (EEG) was recorded for 15 min before and after each session to assess neurophysiological changes, as well as 24 h after the final session. Clinical outcomes included seizure frequency (number per day) and intensity (qualitatively assessed based on amplitude and duration of motor jerks), derived from seizure diaries. AEs were systematically recorded throughout treatment and follow-up to monitor the safety of the treatment. Long-term outcomes were assessed during post-treatment clinical visits.</p></sec></sec><sec id="Sec6"><title>Results and discussion</title><sec id="Sec7"><title>Patient 1</title><p id="Par43">A 23-year-old male with intractable EPC since age 10 presented with increased seizure frequency and difficulty maintaining therapeutic ASM levels. At admission, the patient averaged 11 seizures/day during the prior week. His typical seizures involved left-sided jerking movements, primarily affecting his hand, but sometimes extending to his left leg and face, causing head deviation and impaired walking. Occasionally, seizures progressed to secondary generalized bilateral tonic&#x02013;clonic seizures. In addition, the patient suffered from constant jerks on the left side of his body, predominantly in the arm, which worsened by voluntary movement. Previous interventions, including multiple subpial transections in the right frontodorsal, precentral and postcentral areas in 2004, as well as the placement of a vagus nerve stimulator (VNS) in 2006, were unsuccessful. Over the years, various ASMs had been tried without achieving seizure control (Table <xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table 1</label><caption><p>Antiseizure medications tried prior to theta burst stimulation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">Therapy</th><th align="left">Maximum daily dose</th><th align="left">Reason for reduction or discontinuation</th></tr></thead><tbody><tr><td align="left" rowspan="14">1</td><td align="left">Topiramate</td><td align="left">600 mg</td><td align="left">NR</td></tr><tr><td align="left">Carbamazepine</td><td align="left">1000 mg</td><td align="left">NA</td></tr><tr><td align="left">Clobazam</td><td align="left">20 mg</td><td align="left">NA</td></tr><tr><td align="left">Pregabalin</td><td align="left">1200 mg</td><td align="left">Fatigue</td></tr><tr><td align="left">Lacosamide</td><td align="left">400 mg</td><td align="left">Fatigue, dizziness</td></tr><tr><td align="left">Clonazepam</td><td align="left">1 mg</td><td align="left">NA</td></tr><tr><td align="left">Tiagabine</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">Levetiracetam</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">Phenobarbital</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">Phenytoin</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">Lamotrigine</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">Valproate</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">Prednisolone</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left">Intravenous immunoglobulins</td><td align="left">NR</td><td align="left">NR</td></tr><tr><td align="left" rowspan="5">2</td><td align="left">Levetiracetam</td><td align="left">4000 mg</td><td align="left">NA</td></tr><tr><td align="left">Clonazepam</td><td align="left">0.5 mg</td><td align="left">NA</td></tr><tr><td align="left">Lamotrigine</td><td align="left">275 mg</td><td align="left">NR</td></tr><tr><td align="left">Valproate</td><td align="left">1600 mg</td><td align="left">Not effective</td></tr><tr><td align="left">Lacosamide</td><td align="left">300 mg</td><td align="left">NA</td></tr><tr><td align="left" rowspan="5">3</td><td align="left">Levetiracetam</td><td align="left">2000 mg</td><td align="left">Aggression and agitation</td></tr><tr><td align="left">Carbamazepine</td><td align="left">1600 mg</td><td align="left">Hyponatremia and dizziness</td></tr><tr><td align="left">Clonazepam</td><td align="left">5 mg</td><td align="left">NA</td></tr><tr><td align="left">Phenobarbital</td><td align="left">150 mg</td><td align="left">Patient preference</td></tr><tr><td align="left">Pregabalin</td><td align="left">525 mg</td><td align="left">NA</td></tr></tbody></table><table-wrap-foot><p><italic>mg</italic> milligrams, <italic>pd</italic> per day, <italic>NR</italic> Not reported, <italic>NA</italic> Not applicable</p></table-wrap-foot></table-wrap></p><p id="Par44">Upon admission, the patient was on a regimen of phenytoin, topiramate, carbamazepine, clonazepam, pregabalin, and perampanel. Clinical examination revealed first-degree nystagmus on leftward gaze and persistent left arm myoclonus. Multiple technical investigations were conducted (Table <xref rid="Tab2" ref-type="table">2</xref>).
<table-wrap id="Tab2"><label>Table 2</label><caption><p>Technical investigations prior to theta burst stimulation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Patient</th><th align="left">Technical investigation</th><th align="left">Result</th></tr></thead><tbody><tr><td align="left" rowspan="5">1</td><td align="left">3 T MRI</td><td align="left">Previously documented subpial transections in the right cerebral hemisphere +&#x02009;mild progression of cerebral atrophy on the right side compared to prior MRI</td></tr><tr><td align="left">VEM</td><td align="left">Continuous epileptic activity over the right hemisphere, with a central focus</td></tr><tr><td align="left">Invasive VEM* (subdural grid right centroparietal cortex)</td><td align="left">Continuous epileptic activity over the right hemisphere, with a central focus</td></tr><tr><td align="left">iSPECT</td><td align="left">Left mesiotemporal hyperperfusion</td></tr><tr><td align="left">MEG</td><td align="left">Focal epilepsy originating from the right central cortex, with frequent propagation</td></tr><tr><td align="left" rowspan="6">2</td><td align="left">1.5 T MRI</td><td align="left">Extensive corticosubcortical damage with cortical laminar necrosis +&#x02009;widespread gliotic changes bilaterally (L &#x0003e;&#x02009;R) +&#x02009;cortical hemosiderin deposition in affected areas</td></tr><tr><td align="left">F-18 FDG-PET</td><td align="left">Left medial frontoparietal laminar necrosis</td></tr><tr><td align="left">MR spectroscopy</td><td align="left">Left medial frontoparietal laminar necrosis</td></tr><tr><td align="left">Full-body PET</td><td align="left">No signs of lymphoma or malignancy</td></tr><tr><td align="left">Cerebral angiography</td><td align="left">No features suggestive of vasculitis</td></tr><tr><td align="left">Brain biopsy</td><td align="left">Several possible differential diagnoses, including infectious etiology, Rasmussen encephalitis, and subacute sclerosing panencephalitis</td></tr><tr><td align="left" rowspan="5">3</td><td align="left">1.5 T MRI</td><td align="left">Post-surgical changes after right frontal trepanation +&#x02009;right frontal anterior, Rolandic and parietal tissue loss, with associated cystic encephalomalacia</td></tr><tr><td align="left">VEM</td><td align="left">Focus at the level of the right hemisphere. The nature of the seizures could be compatible with a temporal origin</td></tr><tr><td align="left">F-18 FDG-PET CT</td><td align="left">Right prefrontal and insular hypometabolism</td></tr><tr><td align="left">Brain biopsy</td><td align="left">Tissue with a low degree of gliosis and microglial activation, not compatible with Rasmussen encephalitis, cortical dysplasia or neural storage disease</td></tr><tr><td align="left">Invasive VEM</td><td align="left">NR</td></tr></tbody></table><table-wrap-foot><p><italic>T</italic>&#x000a0;Tesla, <italic>MRI</italic> Magnetic resonance imaging, <italic>VEM</italic> Video-EEG monitoring, <italic>iSPECT</italic> Ictal single-photon emission computed tomography, <italic>MEG</italic> Magnetoencephalography, <italic>L</italic> Left,<italic> R</italic> Right, <italic>FDG-PET</italic> Fluorodeoxyglucose position emission tomography, <italic>PET</italic> Position emission tomography, <italic>CT</italic> Computed tomography, <italic>NR</italic> Not reported</p><p><sup>*</sup>conducted before the subpial transections</p></table-wrap-foot></table-wrap></p><p id="Par45">During admission, the patient was treated with intravenous (IV) clonazepam, which reduced seizure activity to baseline levels. Afterwards, the clinical team proceeded with cTBS as a therapeutic intervention. In the event of a positive response, chronic cortical stimulation (CCS) would be considered as a long-term treatment option. The patient experienced a seizure during and following the first stimulation session. On the second day, two seizures occurred during stimulation; on the third day, two seizures were recorded between stimulation trains.</p><p id="Par46">In the week preceding cTBS, a median of 11 seizures per day (range: 7&#x02013;14) was recorded. Following cTBS, this number decreased to a median of 8 seizures per day (range: 5&#x02013;11), representing a 17% seizure reduction (77 per week vs. 64 per week). However, this reduction was not considered clinically significant. EEG recordings showed no notable changes in epileptiform discharges.</p></sec><sec id="Sec8"><title>Patient 2</title><p id="Par47">A 31-year-old male with intractable EPC since August 2014, likely due to seronegative Rasmussen encephalitis, presented clinical deterioration. His epilepsy was characterized by continuous right-sided jerking movements, primarily affecting the arm and shoulder. Previously, he experienced focal seizures involving jerks on the right side of the mouth and focal seizures with paresthesia in the left arm, both of which had resolved with lamotrigine. Despite various ASMs and immunomodulatory treatments, the continuous jerks had not improved (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par48">Upon admission, the patient was on a regimen of levetiracetam, lamotrigine, clonazepam, lacosamide, methylprednisolone, rituximab and acyclovir. Clinical examination revealed spastic right-sided hemiparesis with neglect, motor aphasia, and continuous jerking movements affecting the right hemisoma, predominantly the right arm. The jerking movements were presumed to be of epileptic origin rather than spasticity-related, based on their rhythmic and stereotyped nature and a history of focal seizures in this area. Multiple technical investigations were performed (Table <xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par49">The clinical team decided to administer cTBS. During one session, involuntary jerks were observed in the chin instead of the hand. The patient tolerated treatment well and experienced no AEs.</p><p id="Par50">While the patient reported no changes, his partner observed a slight improvement in intermittent shoulder jerks. The 15-min EEG conducted after the first session was of poor recording quality, and no EEGs were performed following the second, third or fourth session. Notably, tizanidine was initiated during treatment. Regarding seizure reduction, cTBS was deemed ineffective.</p></sec><sec id="Sec9"><title>Patient 3</title><p id="Par51">A 52-year-old female with intractable EPC since 9 months of age presented with inadequate seizure control. Her seizures were characterized by dystonic flexion of the left arm, occasionally accompanied by jerking movements in the left shoulder. Additionally, the patient experienced continuous jerking in the left hand, which worsened under stress. In the past, she once had jerking movements affecting the left eye and mouth, associated with eye deviation, linked to an infection. Although VNS implantation in 1994 resulted in some seizure frequency reduction, her epilepsy remained insufficiently controlled. Consequently, in November 2004, she underwent right frontodorsal and parietal topectomies, along with transpial resections of the pre- and postcentral gyrus, to address a congenital cortical malformation. In 2010, the VNS battery and electrode were replaced due to a lead breakage. Over the years, various ASMs had been ineffective (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p id="Par52">Upon admission, the patient was on a regimen of pregabalin, carbamazepine, and clonazepam. Clinical examination revealed left hemiparesis, swan-neck deformities of the left hand, slurred speech, saccadic eye movements, first-degree horizontal gaze nystagmus, and continuous jerking of the left hand. Multiple technical investigations were performed (Table <xref rid="Tab2" ref-type="table">2</xref>).</p><p id="Par53">The clinical team decided to initiate cTBS. The VNS was turned off during the magnetic TBS treatment and reactivated afterwards, with its functionality checked after each stimulation session. During treatment, the patient experienced an exacerbation of chronic headaches, effectively managed with 1&#x02009;g paracetamol.</p><p id="Par54">Subjectively, the patient experienced a reduction in the tension of her left arm up until two weeks after the final stimulation session, though this was not externally observed. The 15-min EEGs conducted before and after each session showed no significant changes regarding the right-sided slowing and sporadic epileptic discharges.</p></sec></sec><sec id="Sec10"><title>Discussion</title><p id="Par55">In this case series, a novel 4-day cTBS protocol failed to achieve a clinically meaningful reduction in seizure frequency. While one patient experienced a modest 17% decrease, two others reported subjective improvements.</p><p id="Par56">Clinical and preclinical research highlights substantial individual variability in neuroplastic responses to TBS protocols. Indeed, only about 25% of individuals exhibit the expected outcomes, suggesting that both intrinsic and extrinsic factors influence responsiveness (Park JH <xref ref-type="bibr" rid="CR28">2022</xref>; Li et al. <xref ref-type="bibr" rid="CR17">2019</xref>). Individual characteristics such as age, gender, handedness, skull morphology, and skin properties contribute to this variability, along with external influences like sleep deprivation, fluctuating attention, hormonal fluctuations, and pre-session physical activity (Jannati et al. <xref ref-type="bibr" rid="CR13">2023</xref>; Guerra et al. <xref ref-type="bibr" rid="CR6">2020a</xref>). Genetic factors, including the brain-derived neurotrophic factor Val66Met polymorphism, the ApoE &#x003b5;4 allele, and the catechol-O-methyltransferase Val158Met polymorphism, also play a role (Jannati et al. <xref ref-type="bibr" rid="CR13">2023</xref>; Guerra et al. <xref ref-type="bibr" rid="CR6">2020a</xref>). To mitigate variability, our protocol included measures such as ensuring adequate sleep and avoiding caffeine. Further strategies, such as genetic pre-screening, standardized scheduling to account for circadian rhythms, and age-adjusted stimulation parameters, may enhance consistency (Guerra et al. <xref ref-type="bibr" rid="CR7">2020b</xref>; Opie et al. <xref ref-type="bibr" rid="CR27">2017</xref>)<italic>.</italic></p><p id="Par57">The lack of efficacy contrasts with our previous findings from a systematic review on TMS in refractory SE, where conventional rTMS protocols showed more promising results, although publication bias likely influenced these outcomes (Algoet et al. <xref ref-type="bibr" rid="CR1">2025</xref>). Several factors may explain the absence of therapeutic response in our patients. A higher stimulation intensity, longer ISI, and extended treatment duration may be necessary for clinically meaningful effects. Low-intensity TBS often fails to elicit consistent neuroplastic changes, whereas higher intensities (90&#x02013;120% of rMT) yield more robust effects (Jannati et al. <xref ref-type="bibr" rid="CR13">2023</xref>). Rodent studies suggest that spacing iTBS sessions at least 1&#x02009;h apart enhances previously saturated LTP, whereas shorter intervals fail to elicit additional effects due to less synaptic recruitment (Kram&#x000e1;r et al. <xref ref-type="bibr" rid="CR16">2012</xref>). Clinically, increasing TMS sessions improves response rates in treatment-resistant depression, and extended protocol durations in refractory and super-refractory SE correlate with prolonged seizure control (Algoet et al. <xref ref-type="bibr" rid="CR1">2025</xref>; Yip et al. <xref ref-type="bibr" rid="CR34">2017</xref>). These findings suggest that long-term treatments may be required to induce effects, and that extending the treatment duration for those who did not meet the initial response criteria could potentially have enhanced overall response rates.</p><p id="Par58">Optimizing the targeting approach could further enhance efficacy. In this study, targeting was based on functional identification of the motor area using TMS. While this method is pragmatic in a clinical setting, it may lack the precision of imaging-guided approaches, especially when combined with neuronavigation. Source localization, using EEG or integrated EEG-MRI data, could provide additional benefits by identifying the epileptogenic zone with greater spatial accuracy, allowing for more precise targeting. Studies using different coil orientations &#x02013; such as anterior&#x02013;posterior versus latero-medial &#x02013; indicate that latency variations in evoked potentials can predict whether an individual will respond to cTBS/iTBS or show an opposite effect (Hamada et al. <xref ref-type="bibr" rid="CR9">1991</xref>). These inter-individual differences may stem from variations in intracortical network recruitment. Furthermore, large cerebral lesions alter head conductivity and electrical field distributions, raising concerns about the validity of targeting assumptions derived from healthy subjects (Minjoli et al. <xref ref-type="bibr" rid="CR23">2017</xref>). Secondary macrostructural changes such as cortical atrophy may further influence the field patterns (Minjoli et al. <xref ref-type="bibr" rid="CR23">2017</xref>). However, Minjoli et al. found that TMS-induced electrical fields using a figure-of-eight coil remained largely unchanged in lesioned brains (Minjoli et al. <xref ref-type="bibr" rid="CR23">2017</xref>).</p><p id="Par59">Homeostatic metaplasticity is a concept suggesting that the history of postsynaptic neuronal activity regulates both the magnitude and direction of stimulation-induced plasticity, maintaining synaptic modifications within a functional range (Mastroeni et al. <xref ref-type="bibr" rid="CR21">2013</xref>). This concept supports the use of priming stimulation protocols to optimize neuromodulatory outcomes. Studies demonstrate that excitatory iTBS priming enhances the inhibitory effects of subsequent cTBS on the motor cortex (Todd et al. <xref ref-type="bibr" rid="CR30">2009</xref>). Thus, incorporating iTBS priming into our protocol could have potentiated the inhibitory effects of cTBS. Experimental data highlight the N-methyl-D-aspartate receptor (NMDA-R) NR2 A/NR2B subunit ratio as a key regulator of metaplasticity, with a lower ratio favoring LTP over LTD (Murakami et al. <xref ref-type="bibr" rid="CR24">2012</xref>). In SE, selective NMDA-R trafficking and NR2B-subunit upregulation may predispose synapses to LTP, thereby counteracting the desired LTD effects of cTBS and diminishing its therapeutic efficacy (San-juan et al. <xref ref-type="bibr" rid="CR29">2019</xref>; Naylor <xref ref-type="bibr" rid="CR26">2013</xref>).</p><p id="Par60">Finally, the influence of ASMs on treatment efficacy must be considered. While most research focuses on LTP, some ASMs, such as lamotrigine and NMDA-R antagonists, suppress LTD-like effects (Table <xref rid="Tab3" ref-type="table">3</xref>)(Hamed <xref ref-type="bibr" rid="CR10">2020</xref>). One of our patients was taking lamotrigine, which may have influenced treatment outcomes. Given that epilepsy patients in neuromodulation studies often receive multiple ASMs, future research should clarify the impact on TMS-induced plasticity and explore strategies to minimize pharmacological confounds in neuromodulation trials.
<table-wrap id="Tab3"><label>Table 3</label><caption><p>Effect of antiseizure medication on plasticity</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">ASM</th><th align="left">Effect on plasticity</th></tr></thead><tbody><tr><td align="left">Levetiracetam</td><td align="left">Significant suppression LTP-like plasticity in human M1</td></tr><tr><td align="left">Carbamazepine</td><td align="left">&#x02193; facilitation</td></tr><tr><td align="left">Gabapentin</td><td align="left"><p>&#x02193; facilitation</p><p>No effect on LTP-like MEP response</p></td></tr><tr><td align="left">Lamotrigine</td><td align="left"><p>Decreased LTP-like MEP response</p><p>Decreased LTD-like MEP response</p></td></tr><tr><td align="left">Topiramate</td><td align="left"><p>&#x02193; facilitation</p><p>No effect on LTP-like MEP response</p></td></tr><tr><td align="left">Ethosuximide</td><td align="left">Reversed the LTP-like response</td></tr><tr><td align="left">NMDA-R antagonist</td><td align="left"><p>Decreased LTP</p><p>Decreased LTD</p></td></tr><tr><td align="left">Diazepam</td><td align="left">Trend-level on LTP-like MEP response</td></tr></tbody></table><table-wrap-foot><p><italic>ASM</italic> Antiseizure medication, <italic>LTP</italic> Long-term potentiation, <italic>M1</italic> Primary motor cortex, <italic>MEP</italic> Motor-evoked potential, <italic>NMDA-R</italic> N-methyl-D-aspartate receptor, <italic>LTD</italic> Long-term depression</p></table-wrap-foot></table-wrap></p><p id="Par61">Our recent systematic review reported a cessation rate of 70.6% in EPC patients following the administration of rTMS (Algoet et al. <xref ref-type="bibr" rid="CR1">2025</xref>). Although TBS has shown efficacy comparable to conventional rTMS in disorders such as depression, this equivalence may not extend to SE. Given the small sample size in the present study, any assertion regarding the potential superiority of one stimulation protocol over another remains speculative. Robust conclusions will require further trials, which remain challenging in this complex patient population.</p><p id="Par62">In this case series, one patient experienced seizures during and after stimulation. However, given the pre-treatment median of 11 seizures per day, it remains unclear whether this was treatment-related or coincidental. Overall, our findings suggest the preliminary safety of cTBS in patients with EPC, consistent with previous studies that employed single cTBS trains in individuals with idiopathic generalized epilepsy and more intensive cTBS protocols in patients with drug-resistant epilepsy (DRE)(Carrette et al. <xref ref-type="bibr" rid="CR2">2022</xref>; Koc et al. <xref ref-type="bibr" rid="CR15">2017</xref>; Gundogdu Celebi et al. <xref ref-type="bibr" rid="CR8">2023</xref>).</p></sec><sec id="Sec11"><title>Conclusion</title><p id="Par63">This is the first published case series investigating cTBS as a treatment for EPC. While our findings do not support a clinically meaningful seizure-reducing effect, they suggest preliminary safety. We advocate for further exploration of this approach following protocol optimization, including increased stimulation intensity, extended ISI, prolonged treatment duration for non-responders, refined target localization via neuronavigation and source imaging, optimized coil orientation, and incorporated priming techniques. Furthermore, structural abnormalities may alter the induced electrical field pattern, and ASMs can influence cortical excitability and plasticity. The substantial inter-individual variability in response to TBS challenges the feasibility of a one-size-fits-all approach, underscoring the need for personalized treatment protocols. Further research should focus on optimizing stimulation parameters, integrating predictive biomarkers, and establishing clear patient selection criteria to enhance the efficacy of cTBS in EPC.</p></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>AEs</term><def><p id="Par5">Adverse events</p></def></def-item><def-item><term>ASMs</term><def><p id="Par6">Antiseizure medications</p></def></def-item><def-item><term>CCS</term><def><p id="Par7">Chronic cortical stimulation</p></def></def-item><def-item><term>cTBS</term><def><p id="Par8">Continuous theta burst stimulation</p></def></def-item><def-item><term>DRE</term><def><p id="Par9">Drug-resistant epilepsy</p></def></def-item><def-item><term>EEG(s)</term><def><p id="Par10">Electroencephalogram(s)</p></def></def-item><def-item><term>EPC</term><def><p id="Par11">Epilepsia partialis continua</p></def></def-item><def-item><term>FDA</term><def><p id="Par12">Food and Drug Administration</p></def></def-item><def-item><term>GABA</term><def><p id="Par13">Gamma-aminobutyric acid</p></def></def-item><def-item><term>GABA-A-R</term><def><p id="Par14">Gamma-aminobutyric acid receptor</p></def></def-item><def-item><term>HF-rTMS</term><def><p id="Par15">High-frequency repetitive transcranial magnetic stimulation</p></def></def-item><def-item><term>ISI</term><def><p id="Par16">Interstimulus interval</p></def></def-item><def-item><term>iTBS</term><def><p id="Par17">Intermittent theta burst stimulation</p></def></def-item><def-item><term>IV</term><def><p id="Par18">Intravenous</p></def></def-item><def-item><term>LF-rTMS</term><def><p id="Par19">Low-frequency repetitive transcranial magnetic stimulation</p></def></def-item><def-item><term>LTD</term><def><p id="Par20">Long-term depression</p></def></def-item><def-item><term>LTP</term><def><p id="Par21">Long-term potentiation</p></def></def-item><def-item><term>NMDAR</term><def><p id="Par22">N-methyl-D-aspartate receptor</p></def></def-item><def-item><term>rMT</term><def><p id="Par23">Resting motor threshold</p></def></def-item><def-item><term>rTMS</term><def><p id="Par24">Repetitive transcranial magnetic stimulation</p></def></def-item><def-item><term>SE</term><def><p id="Par25">Status epilepticus</p></def></def-item><def-item><term>TBS</term><def><p id="Par26">Theta burst stimulation</p></def></def-item><def-item><term>TMS</term><def><p id="Par27">Transcranial magnetic stimulation</p></def></def-item><def-item><term>VNS</term><def><p id="Par28">Vagal nerve stimulation</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Publisher&#x02019;s Note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><ack><title>Acknowledgements</title><p>Not applicable.</p></ack><notes notes-type="author-contribution"><title>Authors&#x02019; contributions</title><p>C.A. drafted the main manuscript. S.C. was responsible for the conceptualization and investigation. All authors critically reviewed and approved the final manuscript.</p></notes><notes notes-type="funding-information"><title>Funding</title><p>This work was supported by the Research Foundation &#x02013; Flanders and the 4Brain research group. </p></notes><notes notes-type="data-availability"><title>Data availability</title><p>No datasets were generated or analysed during the current study.</p></notes><notes><title>Declarations</title><notes id="FPar1"><title>Ethics approval and consent to participate</title><p id="Par64">The study protocol was approved by the ethics committee of Ghent University Hospital and written informed consent was obtained from all participants prior to inclusion. </p></notes><notes id="FPar2"><title>Consent for publication</title><p id="Par65">Not applicable.</p></notes><notes id="FPar3" notes-type="COI-statement"><title>Competing interests</title><p id="Par66">The authors declare no competing interests.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><mixed-citation publication-type="other">Algoet C, Van Rooy K, Boon P, Carrette E, Carrette S, Sprengers M, et al. Repetitive Transcranial Magnetic Stimulation for Refractory and Super-refractory Status Epilepticus: A Systematic Review. Neuromodulation J Int Neuromodulation Soc. 2025;S1094&#x02013;7159(25)00030&#x02013;3.</mixed-citation></ref><ref id="CR2"><mixed-citation publication-type="other">Carrette S, Boon P, Klooster D, Van Dycke A, CarretteCarrette E, Miatton M, et al. Continuous theta burst stimulation for drug-resistant epilepsy. Front Neurosci. 17 augustus 2022;16. Beschikbaar op:&#x000a0;<ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.885905/full">https://www.frontiersin.org/journals/neuroscience/articles/10.3389/fnins.2022.885905/full</ext-link>. geciteerd 14 januari 2025.</mixed-citation></ref><ref id="CR3"><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name><surname>Chung</surname><given-names>SW</given-names></name><name><surname>Hoy</surname><given-names>KE</given-names></name><name><surname>Fitzgerald</surname><given-names>PB</given-names></name></person-group><article-title>Theta-burst stimulation: a new form of TMS treatment for depression?</article-title><source>Depress Anxiety Maart</source><year>2015</year><volume>32</volume><issue>3</issue><fpage>182</fpage><lpage>192</lpage><pub-id pub-id-type="doi">10.1002/da.22335</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Chung SW, Hoy KE, Fitzgerald PB. Theta-burst stimulation: a new form of TMS treatment for depression? Depress Anxiety Maart. 2015;32(3):182&#x02013;92.</mixed-citation></citation-alternatives></ref><ref id="CR4"><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name><surname>Cole</surname><given-names>E</given-names></name><name><surname>O&#x02019;Sullivan</surname><given-names>SJ</given-names></name><name><surname>Tik</surname><given-names>M</given-names></name><name><surname>Williams</surname><given-names>NR</given-names></name></person-group><article-title>Accelerated Theta Burst Stimulation: Safety, Efficacy, and Future Advancements</article-title><source>Biol Psychiatry</source><year>2024</year><volume>95</volume><issue>6</issue><fpage>523</fpage><lpage>35</lpage><pub-id pub-id-type="doi">10.1016/j.biopsych.2023.12.004</pub-id><pub-id pub-id-type="pmid">38383091</pub-id>
</element-citation><mixed-citation id="mc-CR4" publication-type="journal">Cole E, O&#x02019;Sullivan SJ, Tik M, Williams NR. Accelerated Theta Burst Stimulation: Safety, Efficacy, and Future Advancements. Biol Psychiatry. 2024;95(6):523&#x02013;35.<pub-id pub-id-type="pmid">38383091</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR5"><mixed-citation publication-type="other">Kravljanac R, Djuric M, Jovic N, Djordjevic M, Zamurovic D, Pekmezovic T. Etiology, clinical features and outcome of epilepsia partialis continua in cohort of 51 children. Epilepsy Res. maart. 2013;104(1-2):112&#x02013;7. </mixed-citation></ref><ref id="CR6"><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Alonso</surname><given-names>V</given-names></name><name><surname>Cheeran</surname><given-names>B</given-names></name><name><surname>Suppa</surname><given-names>A</given-names></name></person-group><article-title>Variability in non-invasive brain stimulation studies: Reasons and results</article-title><source>Neurosci Lett</source><year>2020</year><volume>719</volume><fpage>133330</fpage><pub-id pub-id-type="doi">10.1016/j.neulet.2017.12.058</pub-id><pub-id pub-id-type="pmid">29294333</pub-id>
</element-citation><mixed-citation id="mc-CR6" publication-type="journal">Guerra A, L&#x000f3;pez-Alonso V, Cheeran B, Suppa A. Variability in non-invasive brain stimulation studies: Reasons and results. Neurosci Lett. 2020;719:133330.<pub-id pub-id-type="pmid">29294333</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR7"><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name><surname>Guerra</surname><given-names>A</given-names></name><name><surname>L&#x000f3;pez-Alonso</surname><given-names>V</given-names></name><name><surname>Cheeran</surname><given-names>B</given-names></name><name><surname>Suppa</surname><given-names>A</given-names></name></person-group><article-title>Solutions for managing variability in non-invasive brain stimulation studies</article-title><source>Neurosci Lett</source><year>2020</year><volume>719</volume><fpage>133332</fpage><pub-id pub-id-type="doi">10.1016/j.neulet.2017.12.060</pub-id><pub-id pub-id-type="pmid">29294334</pub-id>
</element-citation><mixed-citation id="mc-CR7" publication-type="journal">Guerra A, L&#x000f3;pez-Alonso V, Cheeran B, Suppa A. Solutions for managing variability in non-invasive brain stimulation studies. Neurosci Lett. 2020;719:133332.<pub-id pub-id-type="pmid">29294334</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR8"><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name><surname>Gundogdu Celebi</surname><given-names>L</given-names></name><name><surname>Sirin</surname><given-names>NG</given-names></name><name><surname>Elmali</surname><given-names>AD</given-names></name><name><surname>Baykan</surname><given-names>B</given-names></name><name><surname>Oge</surname><given-names>AE</given-names></name><name><surname>Bebek</surname><given-names>N</given-names></name></person-group><article-title>Continuous theta-burst stimulation in patients with drug-resistant epilepsy: A single-blind placebo-controlled cross-over pilot study</article-title><source>Neurophysiol Clin</source><year>2023</year><volume>53</volume><issue>3</issue><fpage>102896</fpage><pub-id pub-id-type="doi">10.1016/j.neucli.2023.102896</pub-id><pub-id pub-id-type="pmid">37657363</pub-id>
</element-citation><mixed-citation id="mc-CR8" publication-type="journal">Gundogdu Celebi L, Sirin NG, Elmali AD, Baykan B, Oge AE, Bebek N. Continuous theta-burst stimulation in patients with drug-resistant epilepsy: A single-blind placebo-controlled cross-over pilot study. Neurophysiol Clin. 2023;53(3):102896.<pub-id pub-id-type="pmid">37657363</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR9"><mixed-citation publication-type="other">Hamada M, Murase N, Hasan A, Balaratnam M, Rothwell J. The Role of Interneuron Networks in Driving Human Motor Cortical Plasticity. Cerebral Cortex. 2013;23(7):1593&#x02013;605.</mixed-citation></ref><ref id="CR10"><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name><surname>Hamed</surname><given-names>SA</given-names></name></person-group><article-title>Cortical excitability in epilepsy and the impact of antiepileptic drugs: transcranial magnetic stimulation applications</article-title><source>Expert Rev Neurother Juli</source><year>2020</year><volume>20</volume><issue>7</issue><fpage>707</fpage><lpage>723</lpage><pub-id pub-id-type="doi">10.1080/14737175.2020.1780122</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Hamed SA. Cortical excitability in epilepsy and the impact of antiepileptic drugs: transcranial magnetic stimulation applications. Expert Rev Neurother Juli. 2020;20(7):707&#x02013;23.</mixed-citation></citation-alternatives></ref><ref id="CR11"><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name><surname>Hanhan</surname><given-names>UA</given-names></name><name><surname>Fiallos</surname><given-names>MR</given-names></name><name><surname>Orlowski</surname><given-names>JP</given-names></name></person-group><article-title>Status epilepticus</article-title><source>Pediatr Clin North Am Juni</source><year>2001</year><volume>48</volume><issue>3</issue><fpage>683</fpage><lpage>694</lpage><pub-id pub-id-type="doi">10.1016/S0031-3955(05)70334-5</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Hanhan UA, Fiallos MR, Orlowski JP. Status epilepticus. Pediatr Clin North Am Juni. 2001;48(3):683&#x02013;94.</mixed-citation></citation-alternatives></ref><ref id="CR12"><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>YZ</given-names></name><name><surname>Edwards</surname><given-names>MJ</given-names></name><name><surname>Rounis</surname><given-names>E</given-names></name><name><surname>Bhatia</surname><given-names>KP</given-names></name><name><surname>Rothwell</surname><given-names>JC</given-names></name></person-group><article-title>Theta burst stimulation of the human motor cortex</article-title><source>Neuron</source><year>2005</year><volume>45</volume><issue>2</issue><fpage>201</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2004.12.033</pub-id><pub-id pub-id-type="pmid">15664172</pub-id>
</element-citation><mixed-citation id="mc-CR12" publication-type="journal">Huang YZ, Edwards MJ, Rounis E, Bhatia KP, Rothwell JC. Theta burst stimulation of the human motor cortex. Neuron. 2005;45(2):201&#x02013;6.<pub-id pub-id-type="pmid">15664172</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR13"><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name><surname>Jannati</surname><given-names>A</given-names></name><name><surname>Oberman</surname><given-names>LM</given-names></name><name><surname>Rotenberg</surname><given-names>A</given-names></name><name><surname>Pascual-Leone</surname><given-names>A</given-names></name></person-group><article-title>Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation</article-title><source>Neuropsychopharmacology</source><year>2023</year><volume>48</volume><issue>1</issue><fpage>191</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1038/s41386-022-01453-8</pub-id><pub-id pub-id-type="pmid">36198876</pub-id>
</element-citation><mixed-citation id="mc-CR13" publication-type="journal">Jannati A, Oberman LM, Rotenberg A, Pascual-Leone A. Assessing the mechanisms of brain plasticity by transcranial magnetic stimulation. Neuropsychopharmacology. 2023;48(1):191&#x02013;208.<pub-id pub-id-type="pmid">36198876</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR14"><mixed-citation publication-type="other">Khan Z, Arya K, Bollu PC. Epilepsia Partialis Continua. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2024. Beschikbaar op: <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK532275/">https://www.ncbi.nlm.nih.gov/books/NBK532275/</ext-link>. geciteerd 2 oktober 2024.</mixed-citation></ref><ref id="CR15"><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name><surname>Koc</surname><given-names>G</given-names></name><name><surname>Gokcil</surname><given-names>Z</given-names></name><name><surname>Bek</surname><given-names>S</given-names></name><name><surname>Kasikci</surname><given-names>T</given-names></name><name><surname>Eroglu</surname><given-names>E</given-names></name><name><surname>Odabasi</surname><given-names>Z</given-names></name></person-group><article-title>Effects of continuous theta burst transcranial magnetic stimulation on cortical excitability in patients with idiopathic generalized epilepsy</article-title><source>Epilepsy Behav EB December</source><year>2017</year><volume>77</volume><fpage>26</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/j.yebeh.2017.09.011</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Koc G, Gokcil Z, Bek S, Kasikci T, Eroglu E, Odabasi Z. Effects of continuous theta burst transcranial magnetic stimulation on cortical excitability in patients with idiopathic generalized epilepsy. Epilepsy Behav EB December. 2017;77:26&#x02013;9.</mixed-citation></citation-alternatives></ref><ref id="CR16"><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name><surname>Kram&#x000e1;r</surname><given-names>EA</given-names></name><name><surname>Babayan</surname><given-names>AH</given-names></name><name><surname>Gavin</surname><given-names>CF</given-names></name><name><surname>Cox</surname><given-names>CD</given-names></name><name><surname>Jafari</surname><given-names>M</given-names></name><name><surname>Gall</surname><given-names>CM</given-names></name></person-group><article-title>Synaptic evidence for the efficacy of spaced learning</article-title><source>Proc Natl Acad Sci U S A</source><year>2012</year><volume>109</volume><issue>13</issue><fpage>5121</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1073/pnas.1120700109</pub-id><pub-id pub-id-type="pmid">22411798</pub-id>
</element-citation><mixed-citation id="mc-CR16" publication-type="journal">Kram&#x000e1;r EA, Babayan AH, Gavin CF, Cox CD, Jafari M, Gall CM. Synaptic evidence for the efficacy of spaced learning. Proc Natl Acad Sci U S A. 2012;109(13):5121&#x02013;6.<pub-id pub-id-type="pmid">22411798</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR17"><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>CT</given-names></name><name><surname>Huang</surname><given-names>YZ</given-names></name><name><surname>Bai</surname><given-names>YM</given-names></name><name><surname>Tsai</surname><given-names>SJ</given-names></name><name><surname>Su</surname><given-names>TP</given-names></name><name><surname>Cheng</surname><given-names>CM</given-names></name></person-group><article-title>Critical role of glutamatergic and GABAergic neurotransmission in the central mechanisms of theta burst stimulation</article-title><source>Hum Brain Mapp</source><year>2019</year><volume>40</volume><issue>6</issue><fpage>2001</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1002/hbm.24485</pub-id><pub-id pub-id-type="pmid">30600571</pub-id>
</element-citation><mixed-citation id="mc-CR17" publication-type="journal">Li CT, Huang YZ, Bai YM, Tsai SJ, Su TP, Cheng CM. Critical role of glutamatergic and GABAergic neurotransmission in the central mechanisms of theta burst stimulation. Hum Brain Mapp. 2019;40(6):2001&#x02013;9.<pub-id pub-id-type="pmid">30600571</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR18"><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Xing</surname><given-names>W</given-names></name><name><surname>Zhu</surname><given-names>K</given-names></name></person-group><article-title>Efficacy and Safety of Theta Burst Versus Repetitive Transcranial Magnetic Stimulation for the Treatment of Depression: A Meta-Analysis of Randomized Controlled Trials</article-title><source>Neuromodulation </source><year>2024</year><volume>27</volume><issue>4</issue><fpage>701</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1016/j.neurom.2023.08.009</pub-id><pub-id pub-id-type="pmid">37831019</pub-id>
</element-citation><mixed-citation id="mc-CR18" publication-type="journal">Liu C, Li L, Li B, Liu Z, Xing W, Zhu K. Efficacy and Safety of Theta Burst Versus Repetitive Transcranial Magnetic Stimulation for the Treatment of Depression: A Meta-Analysis of Randomized Controlled Trials. Neuromodulation. 2024;27(4):701&#x02013;10.<pub-id pub-id-type="pmid">37831019</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR19"><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>DH</given-names></name><name><surname>Alldredge</surname><given-names>BK</given-names></name></person-group><article-title>Status epilepticus</article-title><source>N Engl J Med</source><year>1998</year><volume>338</volume><issue>14</issue><fpage>970</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1056/NEJM199804023381407</pub-id><pub-id pub-id-type="pmid">9521986</pub-id>
</element-citation><mixed-citation id="mc-CR19" publication-type="journal">Lowenstein DH, Alldredge BK. Status epilepticus. N Engl J Med. 1998;338(14):970&#x02013;6.<pub-id pub-id-type="pmid">9521986</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR20"><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name><surname>Mameni&#x00161;kien&#x00117;</surname><given-names>R</given-names></name><name><surname>Wolf</surname><given-names>P</given-names></name></person-group><article-title>Epilepsia partialis continua: A review</article-title><source>Seizure</source><year>2017</year><volume>44</volume><fpage>74</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1016/j.seizure.2016.10.010</pub-id><pub-id pub-id-type="pmid">28029552</pub-id>
</element-citation><mixed-citation id="mc-CR20" publication-type="journal">Mameni&#x00161;kien&#x00117; R, Wolf P. Epilepsia partialis continua: A review. Seizure. 2017;44:74&#x02013;80.<pub-id pub-id-type="pmid">28029552</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR21"><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name><surname>Mastroeni</surname><given-names>C</given-names></name><name><surname>Bergmann</surname><given-names>TO</given-names></name><name><surname>Rizzo</surname><given-names>V</given-names></name><name><surname>Ritter</surname><given-names>C</given-names></name><name><surname>Klein</surname><given-names>C</given-names></name><name><surname>Pohlmann</surname><given-names>I</given-names></name></person-group><article-title>Brain-derived neurotrophic factor--a major player in stimulation-induced homeostatic metaplasticity of human motor cortex?</article-title><source>PloS One</source><year>2013</year><volume>8</volume><issue>2</issue><fpage>e57957</fpage><pub-id pub-id-type="doi">10.1371/journal.pone.0057957</pub-id><pub-id pub-id-type="pmid">23469118</pub-id>
</element-citation><mixed-citation id="mc-CR21" publication-type="journal">Mastroeni C, Bergmann TO, Rizzo V, Ritter C, Klein C, Pohlmann I, et al. Brain-derived neurotrophic factor--a major player in stimulation-induced homeostatic metaplasticity of human motor cortex?. PloS One. 2013;8(2):e57957.<pub-id pub-id-type="pmid">23469118</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR22"><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name><surname>Mattioli</surname><given-names>F</given-names></name><name><surname>Maglianella</surname><given-names>V</given-names></name><name><surname>D&#x02019;Antonio</surname><given-names>S</given-names></name><name><surname>Trimarco</surname><given-names>E</given-names></name><name><surname>Caligiore</surname><given-names>D</given-names></name></person-group><article-title>Non-invasive brain stimulation for patients and healthy subjects: Current challenges and future perspectives</article-title><source>J Neurol Sci</source><year>2024</year><volume>456</volume><fpage>122825</fpage><pub-id pub-id-type="doi">10.1016/j.jns.2023.122825</pub-id><pub-id pub-id-type="pmid">38103417</pub-id>
</element-citation><mixed-citation id="mc-CR22" publication-type="journal">Mattioli F, Maglianella V, D&#x02019;Antonio S, Trimarco E, Caligiore D. Non-invasive brain stimulation for patients and healthy subjects: Current challenges and future perspectives. J Neurol Sci. 2024;456:122825.<pub-id pub-id-type="pmid">38103417</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR23"><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name><surname>Minjoli</surname><given-names>S</given-names></name><name><surname>Saturnino</surname><given-names>GB</given-names></name><name><surname>Blicher</surname><given-names>JU</given-names></name><name><surname>Stagg</surname><given-names>CJ</given-names></name><name><surname>Siebner</surname><given-names>HR</given-names></name><name><surname>Antunes</surname><given-names>A</given-names></name></person-group><article-title>The impact of large structural brain changes in chronic stroke patients on the electric field caused by transcranial brain stimulation</article-title><source>NeuroImage Clin</source><year>2017</year><volume>15</volume><fpage>106</fpage><lpage>17</lpage><pub-id pub-id-type="doi">10.1016/j.nicl.2017.04.014</pub-id><pub-id pub-id-type="pmid">28516033</pub-id>
</element-citation><mixed-citation id="mc-CR23" publication-type="journal">Minjoli S, Saturnino GB, Blicher JU, Stagg CJ, Siebner HR, Antunes A, et al. The impact of large structural brain changes in chronic stroke patients on the electric field caused by transcranial brain stimulation. NeuroImage Clin. 2017;15:106&#x02013;17.<pub-id pub-id-type="pmid">28516033</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR24"><citation-alternatives><element-citation id="ec-CR24" publication-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>M&#x000fc;ller-Dahlhaus</surname><given-names>F</given-names></name><name><surname>Lu</surname><given-names>MK</given-names></name><name><surname>Ziemann</surname><given-names>U</given-names></name></person-group><article-title>Homeostatic metaplasticity of corticospinal excitatory and intracortical inhibitory neural circuits in human motor cortex</article-title><source>J Physiol</source><year>2012</year><volume>590</volume><issue>22</issue><fpage>5765</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2012.238519</pub-id><pub-id pub-id-type="pmid">22930265</pub-id>
</element-citation><mixed-citation id="mc-CR24" publication-type="journal">Murakami T, M&#x000fc;ller-Dahlhaus F, Lu MK, Ziemann U. Homeostatic metaplasticity of corticospinal excitatory and intracortical inhibitory neural circuits in human motor cortex. J Physiol. 2012;590(22):5765&#x02013;81.<pub-id pub-id-type="pmid">22930265</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR25"><citation-alternatives><element-citation id="ec-CR25" publication-type="journal"><person-group person-group-type="author"><name><surname>Muthaffar</surname><given-names>OY</given-names></name><name><surname>Alyazidi</surname><given-names>AS</given-names></name></person-group><article-title>Epilepsia partialis continua: A review</article-title><source>Neurosciences</source><year>2024</year><volume>29</volume><issue>2</issue><fpage>71</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.17712/nsj.2024.2.20230074</pub-id><pub-id pub-id-type="pmid">38740401</pub-id>
</element-citation><mixed-citation id="mc-CR25" publication-type="journal">Muthaffar OY, Alyazidi AS. Epilepsia partialis continua: A review. Neurosciences. 2024;29(2):71&#x02013;6.<pub-id pub-id-type="pmid">38740401</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR26"><citation-alternatives><element-citation id="ec-CR26" publication-type="journal"><person-group person-group-type="author"><name><surname>Naylor</surname><given-names>DE</given-names></name></person-group><article-title>In the fast lane: Receptor trafficking during status epilepticus</article-title><source>Epilepsia Open</source><year>2023</year><volume>8</volume><issue>Suppl 1</issue><fpage>S35</fpage><lpage>65</lpage><pub-id pub-id-type="pmid">36861477</pub-id>
</element-citation><mixed-citation id="mc-CR26" publication-type="journal">Naylor DE. In the fast lane: Receptor trafficking during status epilepticus. Epilepsia Open. 2023;8(Suppl 1):S35-65.<pub-id pub-id-type="pmid">36861477</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR27"><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name><surname>Opie</surname><given-names>GM</given-names></name><name><surname>Vosnakis</surname><given-names>E</given-names></name><name><surname>Ridding</surname><given-names>MC</given-names></name><name><surname>Ziemann</surname><given-names>U</given-names></name><name><surname>Semmler</surname><given-names>JG</given-names></name></person-group><article-title>Priming theta burst stimulation enhances motor cortex plasticity in young but not old adults</article-title><source>Brain Stimulat</source><year>2017</year><volume>10</volume><issue>2</issue><fpage>298</fpage><lpage>304</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2017.01.003</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Opie GM, Vosnakis E, Ridding MC, Ziemann U, Semmler JG. Priming theta burst stimulation enhances motor cortex plasticity in young but not old adults. Brain Stimulat. 2017;10(2):298&#x02013;304.</mixed-citation></citation-alternatives></ref><ref id="CR28"><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name><surname>Park</surname><given-names>JH</given-names></name></person-group><article-title>Reliability of theta burst stimulation as a neuromodulation tool</article-title><source>J Neurophysiol</source><year>2022</year><volume>127</volume><issue>6</issue><fpage>1532</fpage><lpage>4</lpage><pub-id pub-id-type="doi">10.1152/jn.00507.2021</pub-id><pub-id pub-id-type="pmid">35544758</pub-id>
</element-citation><mixed-citation id="mc-CR28" publication-type="journal">Park JH. Reliability of theta burst stimulation as a neuromodulation tool. J Neurophysiol. 2022;127(6):1532&#x02013;4.<pub-id pub-id-type="pmid">35544758</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR29"><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name><surname>San-juan</surname><given-names>D</given-names></name><name><surname>D&#x000e1;vila-Rodr&#x000ed;guez</surname><given-names>DO</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>CR</given-names></name><name><surname>Gonz&#x000e1;lez</surname><given-names>MS</given-names></name><name><surname>Carranza</surname><given-names>SM</given-names></name><name><surname>Hern&#x000e1;ndez Mendoza </surname><given-names>JR</given-names></name></person-group><article-title>Neuromodulation techniques for status epilepticus: A review</article-title><source>Brain Stimulat</source><year>2019</year><volume>12</volume><issue>4</issue><fpage>835</fpage><lpage>44</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2019.04.005</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">San-juan D, D&#x000e1;vila-Rodr&#x000ed;guez DO, Jim&#x000e9;nez CR, Gonz&#x000e1;lez MS, Carranza SM, Hern&#x000e1;ndez Mendoza JR, et al. Neuromodulation techniques for status epilepticus: A review. Brain Stimulat. 2019;12(4):835&#x02013;44.</mixed-citation></citation-alternatives></ref><ref id="CR30"><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name><surname>Todd</surname><given-names>G</given-names></name><name><surname>Flavel</surname><given-names>SC</given-names></name><name><surname>Ridding</surname><given-names>MC</given-names></name></person-group><article-title>Priming theta-burst repetitive transcranial magnetic stimulation with low- and high-frequency stimulation</article-title><source>Exp Brain Res Mei</source><year>2009</year><volume>195</volume><issue>2</issue><fpage>307</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.1007/s00221-009-1791-8</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Todd G, Flavel SC, Ridding MC. Priming theta-burst repetitive transcranial magnetic stimulation with low- and high-frequency stimulation. Exp Brain Res Mei. 2009;195(2):307&#x02013;15.</mixed-citation></citation-alternatives></ref><ref id="CR31"><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name><surname>Trinka</surname><given-names>E</given-names></name><name><surname>Cock</surname><given-names>H</given-names></name><name><surname>Hesdorffer</surname><given-names>D</given-names></name><name><surname>Rossetti</surname><given-names>AO</given-names></name><name><surname>Scheffer</surname><given-names>IE</given-names></name><name><surname>Shinnar</surname><given-names>S</given-names></name></person-group><article-title>A definition and classification of status epilepticus &#x02013; Report of the ILAE Task Force on Classification of Status Epilepticus</article-title><source>Epilepsia</source><year>2015</year><volume>56</volume><issue>10</issue><fpage>1515</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1111/epi.13121</pub-id><pub-id pub-id-type="pmid">26336950</pub-id>
</element-citation><mixed-citation id="mc-CR31" publication-type="journal">Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus &#x02013; Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia. 2015;56(10):1515&#x02013;23.<pub-id pub-id-type="pmid">26336950</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR32"><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name><surname>Tsuboyama</surname><given-names>M</given-names></name><name><surname>Kaye</surname><given-names>HL</given-names></name><name><surname>Rotenberg</surname><given-names>A</given-names></name></person-group><article-title>Review of Transcranial Magnetic Stimulation in Epilepsy</article-title><source>Clin Ther Juli</source><year>2020</year><volume>42</volume><issue>7</issue><fpage>1155</fpage><lpage>1168</lpage><pub-id pub-id-type="doi">10.1016/j.clinthera.2020.05.016</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Tsuboyama M, Kaye HL, Rotenberg A. Review of Transcranial Magnetic Stimulation in Epilepsy. Clin Ther Juli. 2020;42(7):1155&#x02013;68.</mixed-citation></citation-alternatives></ref><ref id="CR33"><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>XJ</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>DW</given-names></name><name><surname>Hao</surname><given-names>JM</given-names></name></person-group><article-title>Cerebellar transcranial magnetic stimulation to treat drug-resistant epilepsy: A randomized, controlled, crossover clinical trial</article-title><source>Epilepsia</source><year>2025</year><volume>66</volume><issue>1</issue><fpage>240</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1111/epi.18168</pub-id><pub-id pub-id-type="pmid">39513971</pub-id>
</element-citation><mixed-citation id="mc-CR33" publication-type="journal">Wang YY, Ma L, Shi XJ, Liu Y, Wu DW, Hao JM. Cerebellar transcranial magnetic stimulation to treat drug-resistant epilepsy: A randomized, controlled, crossover clinical trial. Epilepsia. 2025;66(1):240&#x02013;52.<pub-id pub-id-type="pmid">39513971</pub-id>
</mixed-citation></citation-alternatives></ref><ref id="CR34"><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name><surname>Yip</surname><given-names>AG</given-names></name><name><surname>George</surname><given-names>MS</given-names></name><name><surname>Tendler</surname><given-names>A</given-names></name><name><surname>Roth</surname><given-names>Y</given-names></name><name><surname>Zangen</surname><given-names>A</given-names></name><name><surname>Carpenter</surname><given-names>LL</given-names></name></person-group><article-title>61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial</article-title><source>Brain Stimulat</source><year>2017</year><volume>10</volume><issue>4</issue><fpage>847</fpage><lpage>849</lpage><pub-id pub-id-type="doi">10.1016/j.brs.2017.02.013</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Yip AG, George MS, Tendler A, Roth Y, Zangen A, Carpenter LL. 61% of unmedicated treatment resistant depression patients who did not respond to acute TMS treatment responded after four weeks of twice weekly deep TMS in the Brainsway pivotal trial. Brain Stimulat. 2017;10(4):847&#x02013;9.</mixed-citation></citation-alternatives></ref></ref-list></back></article>